With a new wave of Covid-19 cases emerging across the U.S., Pfizer and Moderna have introduced updated mRNA-based vaccines designed to combat the latest strains of the virus. The Food and Drug Administration (FDA) recently approved these vaccines, highlighting the need to adapt as the virus continues to evolve. These updates mark a critical step in the ongoing battle against Covid-19, ensuring that the public remains protected against new and potentially more contagious variants.
The updated vaccines specifically target the KP.2 strain, a descendant of the omicron subvariant JN.1. Although KP.2 was a dominant strain earlier this year, it now accounts for a smaller portion of current cases. However, the new vaccines offer broader protection against other prevalent variants, such as KP.3 and KP.3.1.1. This strategy is similar to the annual updates made to flu vaccines, reflecting the necessity of staying ahead of viral mutations.
Who Should Get the New Covid Vaccines?
The Centers for Disease Control and Prevention (CDC) recommends that everyone aged six months and older receive a dose of the updated Covid vaccine. This guidance underscores the importance of maintaining immunity, especially as new strains emerge. High-risk groups, including individuals aged 65 and older, those who are immunocompromised, and people with underlying medical conditions, are particularly encouraged to get vaccinated to reduce their risk of severe illness.
To maximize the vaccine’s effectiveness, health officials suggest waiting at least two to three months since the last Covid vaccination or a previous infection before receiving the new shot. This waiting period allows the immune system to respond most effectively to the updated vaccine, providing stronger and more lasting protection against the virus.
Where and When to Get Vaccinated
With the FDA’s approval, the new vaccines from Pfizer and Moderna are set to be distributed widely across pharmacies, hospitals, and clinics in the coming days. Major pharmacy chains such as Walgreens, CVS, and Rite-Aid have already started accepting appointments. Walgreens will begin vaccinations for individuals aged 12 and older starting September 6, while CVS and Rite-Aid are also preparing to offer appointments in early September. The CDC plans to relaunch its vaccine appointment locator tool to help people find available vaccination sites.
Deciding the best time to get vaccinated depends on individual circumstances and preferences. While getting vaccinated as soon as possible is advisable to align with the current circulating strains, some may choose to wait until September or October. This timing could provide optimal protection through the winter months and the holiday season when viruses typically spread more rapidly. The updated vaccines are designed to offer sustained immunity, though their effectiveness may gradually decrease over time.
Cost and Accessibility of the Vaccines
Most private insurance plans, along with Medicare and Medicaid, will cover the cost of the updated Covid vaccines, making them accessible to a broad range of the population. Additionally, children can receive free vaccinations through the federally funded Vaccines for Children program, ensuring that younger populations are protected. Although the CDC’s Bridge Access Program for uninsured and underinsured Americans will not be reopening this year, alternative funding has been allocated to ensure those without coverage can still receive the vaccine.
To address this gap, the CDC has allocated $62 million for state and local immunization programs to cover vaccine costs for uninsured and underinsured adults. This funding ensures that financial barriers do not prevent individuals from accessing critical protection against Covid-19. By maintaining comprehensive coverage options, health officials aim to keep vaccination rates high and control the spread of the virus.
Looking Ahead: The Role of Novavax’s Vaccine
Beyond the updated mRNA vaccines from Pfizer and Moderna, Novavax is also entering the scene with a new protein-based vaccine. The company has filed for FDA authorization for a vaccine targeting the JN.1 strain and its descendants, including KP.2.3, KP.3, KP.3.1.1, and LB.1. Novavax is currently in discussions with the FDA, and they expect their vaccine to receive authorization in time for the peak vaccination season in the U.S.
The introduction of Novavax’s protein-based vaccine provides an additional option for those seeking protection against Covid-19. With multiple vaccines available, the public has more opportunities to choose a vaccine that suits their needs and preferences. This variety helps enhance overall immunity in the community, reducing the spread of the virus and offering better protection for everyone.